XML 48 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting
3
SEGMENT REPORTING
For the years ended December 31, 2022, 2023 and 2024, the Group had three operating segments, including central laboratory business,
in-hospital
business and pharma research and development services. The operating segments also represented the reporting segments. The CODM considers year-over-year fluctuations and budget-to-actual variances of the operating segments based on the measures of revenues, cost of revenue and gross profit by central laboratory business,
in-hospital
business and pharma research and development services when assessing performance and deciding how to allocate resources. Other than the information provided below, the CODM does not use any other measures by segment. There are no inter-segment revenue transactions and, therefore, revenues are only generated from external customers. The accounting policies of the segments are the same as those used by the Group. The Group prepared the financial results of the operating segments on a basis that is consistent with the manner in which management internally disaggregates financial information to assist in making internal operating decisions. The reconciliation of gross profit of reportable segments to consolidated loss before income tax was consistent with the consolidated statements of comprehensive loss.
Summarized information by segments for the years ended December 31, 2022, 2023 and 2024 is as follows:
 
    
For the year ended December 31, 2022
  
     Central
laboratory
business		     
In-hospital

business		      Pharma
research and
development
services		      Total  
    
RMB
     
RMB
     
RMB
     
RMB
  
Revenues:
            
Revenues from services
      314,770        3,606        73,172        391,548  
Revenues from sales of products
      —         171,690        —         171,690  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total revenues
   
 
314,770
 
   
 
175,296
 
   
 
73,172
 
   
 
563,238
 
  
 
 
     
 
 
     
 
 
     
 
 
  
Cost of revenues:
   
 
(82,123
) 
   
 
(63,296
) 
   
 
(37,780
) 
   
 
(183,199
) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Gross profit
   
 
232,647
 
   
 
112,000
 
   
 
35,392
 
   
 
380,039
 
  
 
 
     
 
 
     
 
 
     
 
 
  
 
 
    
For the year ended December 31, 2023
  
     Central
laboratory
business		     
In-hospital

business		      Pharma
research and
development
services		      Total  
    
RMB
     
RMB
     
RMB
     
RMB
  
Revenues:
            
Revenues from services
      232,812        (3,704 )       115,922        345,030  
Revenues from sales of products
      —         192,405        —         192,405  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total revenues
   
 
232,812
 
   
 
188,701
 
   
 
115,922
 
   
 
537,435
 
  
 
 
     
 
 
     
 
 
     
 
 
  
Cost of revenues:
   
 
(49,473
) 
   
 
(72,570
) 
   
 
(52,165
) 
   
 
(174,208
) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Gross profit
   
 
183,339
 
   
 
116,131
 
   
 
63,757
 
   
 
363,227
 
  
 
 
     
 
 
     
 
 
     
 
 
  
 
 
    
For the year ended December 31, 2024
  
     Central
laboratory
business		     
In-hospital

business		      Pharma
research and
development
services		      Total  
    
RMB
     
US$
     
RMB
     
US$
     
RMB
     
US$
     
RMB
     
US$
  
Revenues:
                        
Revenues from services
      175,649        24,064        (592 )       (81 )       115,681        15,848        290,738        39,831  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
Revenue from sales of products
      —         —         225,084        30,836        —         —         225,084        30,836  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
Total revenues
   
 
175,649
 
   
 
24,064
 
   
 
224,492
 
   
 
30,755
 
   
 
115,681
 
   
 
15,848
 
   
 
515,822
 
   
 
70,667
 
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
Cost of revenues:
   
 
(33,808
) 
   
 
(4,632
) 
   
 
(65,099
) 
   
 
(8,919
) 
   
 
(54,515
) 
   
 
(7,469
) 
   
 
(153,422
) 
   
 
(21,020
) 
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
Gross profit
   
 
141,841
 
   
 
19,432
 
   
 
159,393
 
   
 
21,836
 
   
 
61,166
 
   
 
8,379
 
   
 
362,400
 
   
 
49,647
 
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
 
 
Geographic information
The analysis of the total long-lived assets excluding equity method investment, convertible note receivable and intangible assets by country was as follows:
 
    
As of December 31,
  
    
2023
     
2024
  
    
RMB
     
RMB
     
US$
  
PRC
      127,866        102,154        13,996  
United States
      21,418        6,112        837  
  
 
 
     
 
 
     
 
 
  
  
 
149,284
 
   
 
108,266
 
   
 
14,833
 
  
 
 
     
 
 
     
 
 
  
Total revenues by geographic area are presented as follows:
 
    
For the year ended December 31,
  
    
2022
     
2023
     
2024
  
    
RMB
     
RMB
     
RMB
     
US$
  
PRC
      553,304        534,928        510,241        69,902  
United States
      9,934        2,507        5,581        765  
  
 
 
     
 
 
     
 
 
     
 
 
  
  
 
563,238
 
   
 
537,435
 
   
 
515,822
 
   
 
70,667